Breakout stocks to purchase or sell: Sumeet Bagadia suggests purchasing five shares today, May 2, 2025

Stock market today: Sumeet Bagadia of Choice Broking believes the Nifty 50 index is facing a hurdle at 25,00. Bagadia believes investors should maintain a stock-specific approach and focus on breakout stocks.

Breakout stocks to buy or sell: CEAT, Kingfa Science and Technolgy (India), Healthcare Global Enterprises, IndoStar Capital Finance, and Alivus Life Sciences are the five shares that Sumeet Bagadia suggests purchasing today.

Breakout stocks buy or sell:For the second consecutive month in April, the Indian stock market maintained its upward trajectory, becoming the best-performing equity market in Asia.

The Sensex saw a 3.2% gain after rising 6% the month before, while the Nifty 50 increased by 3.46% during the month, adding to a 6.30% increase in March. Notably, since falling to their lowest points on April 7, both indices have increased by almost 12%.

The breakout stock recommendations of Sumeet Bagadia
Given that the Nifty 50 index is between 24,050 and 24,350, Choice Broking Executive Director Sumeet Bagadia thinks that the sentiment of the Indian stock market is range-bound.

“A bullish or bearish trend can be assumed on the breakage of either side of this range,” Bagadia said in reference to the Indian stock market’s outlook. The 2025 season is well underway, so it is advisable to stick to a stock-specific strategy and focus on the stocks that appear to be doing well on the technical chart. Examining breakout stocks may be a wise choice.

Breakout stocks to buy or sell: CEAT, Kingfa Science and Technolgy (India), Healthcare Global Enterprises, IndoStar Capital Finance, and Alivus Life Sciences are the five shares that Sumeet Bagadia suggests purchasing today.

Stocks to buy today

1] CEAT: Buy at 3332, target 3555, stop loss 3200;

2] Kingfa Science and Technolgy (India): Buy at 3137.2, target 3350, stop loss 3020;

3] Healthcare Global Enterprises: Buy at 562.45, target 600, stop loss 540;

4] IndoStar Capital Finance: Buy at 301.5, target 322, stop loss 291;

5] Alivus Life Sciences: Buy at 1104, target 1180, stop loss 1070.

Disclaimer: This analysis does not represent the opinions of Mint; rather, it represents the opinions of individual analysts or broking firms. Since market conditions can fluctuate quickly and individual circumstances can differ, we strongly advise investors to seek advice from certified experts before making any investment decisions.

Leave a Reply

Your email address will not be published. Required fields are marked *